Role of factor Xa inhibitors in cancer-associated thrombosis: Any new data?

Advances in Hematology

Volumn 2011, Issue , 2011, Pages

  Zalpour, Ali ^a   Kroll, Michael H ^a   Afshar Kharghan, Vahid ^a   Yusuf, Syed Wamique ^a   Escalante, Carmen ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; DAREXABAN; EDOXABAN; ENOXAPARIN; ERIBAXABAN; FONDAPARINUX; HEPARIN; IDRABIOTAPARINUX; IDRAPARINUX; LETAXABAN; LOW MOLECULAR WEIGHT HEPARIN; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; PLACEBO; PROTAMINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; VITAMIN K GROUP;

ADVANCED CANCER; BLEEDING; CANCER PATIENT; CRITICALLY ILL PATIENT; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; THROMBOSIS; UNDERWEIGHT; VENOUS THROMBOEMBOLISM;

EID: 84855257746     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2011/196135     Document Type: Review

References (74)

1. Varki A., Trousseau's syndrome: multiple definitions and multiple mechanisms Blood 2007 110 6 1723 1729 (Pubitemid 47443881)
2. Bergqvist D., Risk of venous thromboembolism in patients undergoing cancer surgery and options for thromboprophylaxis Journal of Surgical Oncology 2007 95 2 167 174 (Pubitemid 46238988)
3. Stanley A., Young A., Primary prevention of venous thromboembolism in medical and surgical oncology patients British Journal of Cancer 2010 102 1 S10 S16
4. Khorana A. A., Francis C. W., Culakova E., Kuderer N. M., Lyman G. H., Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients Cancer 2007 110 10 2339 2346 (Pubitemid 350100757)
5. National Comprehensive Cancer Network Clinical Practice in Oncology, Venous thromboembolic disease. 2010, http://www.nccn.org/
6. Lyman G. H., Khorana A. A., Falanga A., Clarke-Pearson D., Flowers C., Jahanzeb M., Kakkar A., Kuderer N. M., Levine M. N., Liebman H., Mendelson D., Raskob G., Somerfield M. R., Thodiyil P., Trent D., Francis C. W., American Society of Clinical Oncology Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer Journal of Clinical Oncology 2007 25 34 5490 5505 (Pubitemid 350232226)
7. Geerts W. H., Bergqvist D., Pineo G. F., Heit J. A., Samama C. M., Lassen M. R., Colwell C. W., Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition) Chest 2008 133 6 381S 453S (Pubitemid 351894916)
8. Kearon C., Kahn S. R., Agnelli G., Goldhaber S., Raskob G. E., Comerota A. J., Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition) Chest 2008 133 6 454S 545S (Pubitemid 351892971)
9. Saraiya B., Goodin S., Management of venous thromboembolism and the potential to impact overall survival in patients with cancer Pharmacotherapy 2009 29 11 1344 1356
10. Akl E. A., Kamath G., Yosuico V., Seo Y. K., Barba M., Sperati F., Cook D. J., Schnemann H. J., Thromboprophylaxis for patients with cancer and central venous catheters Cancer 2008 112 11 2483 2492
11. Gross P. L., Weitz J. I., New antithrombotic drugs Clinical Pharmacology and Therapeutics 2009 86 2 139 146
12. Levine M. N., New antithrombotic drugs: potential for use in oncology Journal of Clinical Oncology 2009 27 29 4912 4918
13. Walenga J. M., Jeske W. P., Samama M. M., Frapaise F. X., Bick R. L., Fareed J., Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent Expert Opinion on Investigational Drugs 2002 11 3 397 407 (Pubitemid 34213393)
14. Turpie A. G. G., Fondaparinux: a factor Xa inhibitor for antithrombotic therapy Expert Opinion on Pharmacotherapy 2004 5 6 1373 1384 (Pubitemid 38885795)
15. Reynolds N. A., Perry C. M., Scott L. J., Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery Drugs 2004 64 14 1575 1596 (Pubitemid 38981840)
16. Rupprecht H. J., Blank R., Clinical pharmacology of direct and indirect factor xa inhibitors Drugs 2010 70 16 2153 2170
17. Harenberg J., Development of idraparinux and idrabiotaparinux for anticoagulant therapy Thrombosis and Haemostasis 2009 102 5 811 815
18. GlaxoSmithKline Inc, Arixtra (fondaparinux) Prescribing Information 2010 Research Triangle Park, NC, USA GlaxoSmithKline
19. Ahrens I., Lip G. Y. H., Peter K., New oral anticoagulant drugs in cardiovascular disease Thrombosis and Haemostasis 2010 104 1 49 60
20. Donat F., Duret J. P., Santoni A., Cariou R., Necciari J., Magnani H., De Greef R., The pharmacokinetics of fondaparinux sodium in healthy volunteers Clinical Pharmacokinetics 2002 41 2 1 9 (Pubitemid 35155551)
21. Cohen A. T., Davidson B. L., Gallus A. S., Lassen M. R., Prins M. H., Tomkowski W., Turpie A. G. G., Egberts J. F. M., Lensing A. W. A., Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial British Medical Journal 2006 332 7537 325 327 (Pubitemid 43253745)
22. Turpie A. G. G., Bauer K. A., Caprini J. A., Comp P. C., Gent M., Muntz J. E., Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison Journal of Thrombosis and Haemostasis 2007 5 9 1854 1861 (Pubitemid 47288942)
23. Agnelli G., Bergqvist D., Cohen A. T., Callus A. S., Gent M., Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery British Journal of Surgery 2005 92 10 1212 1220 (Pubitemid 41475229)
24. Bller H. R., Davidson B. L., Decousus H., Gallus A., Gent M., Piovella F., Prins M. H., Raskob G., Van den Berg-Segers A. E. M., Cariou R., Leeuwenkamp O., Lensing A. W. A., Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism The New England Journal of Medicine 2003 349 18 1695 1702 (Pubitemid 37315006)
25. Bller H. R., Davidson B. L., Decousus H., Gallus A., Gent M., Piovella F., Prins M. H., Raskob G., Segers A. E. M., Cariou R., Leeuwenkamp O., Lensing A. W. A., Fondaparinux or enoxaparin for the initial treatment of symptomatic deep vienous thrombosis: a randomized trial Annals of Internal Medicine 2004 140 11
26. Helou R., Should we continue to use the Cockcroft-Gault formula? NephronClinical Practice 2010 116 3 c172 c185
27. van Doormaal F. F., Raskob G. E., Davidson B. L., Decousus H., Gallus A., Lensing A. W. A., Piovella F., Prins M. H., Bller H. R., Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials Thrombosis and Haemostasis 2009 101 4 762 769
28. Davidson B. L., Bller H. R., Decousus H., Gallus A., Gent M., Piovella F., Prins M. H., Raskob G. E., Segers A. E. M., Lensing A. W. A., Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials Journal of Thrombosis and Haemostasis 2007 5 6 1191 1194 (Pubitemid 46902121)
29. Gouin-Thibault I., Pautas E., Mahé I., Descarpentries C., Nivet-Antoine V., Golmard J. L., Siguret V., Is modification of diet in renal disease formula similar to Cockcroft-Gault formula to assess renal function in elderly hospitalized patients treated with low-molecular-weight heparin? Journals of GerontologySeries A 2007 62 11 1300 1305 (Pubitemid 350287620)
30. Melloni C., Peterson E. D., Chen A. Y., Szczech L. A., Newby L. K., Harrington R. A., Gibler W. B., Ohman E. M., Spinler S. A., Roe M. T., Alexander K. P., Cockcroft-gault versus modification of diet in renal disease. Importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes Journal of the American College of Cardiology 2008 51 10 991 996 (Pubitemid 351320612)
31. Turpie A. G. G., Lensing A. W. A., Fuji T., Boyle D. A., Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients Blood Coagulation and Fibrinolysis 2009 20 2 114 121
32. Sombolos K. I., Fragia T. K., Gionanlis L. C., Veneti P. E., Bamichas G. I., Fragidis S. K., Georgoulis I. E., Natse T. A., Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study International Journal of Clinical Pharmacology and Therapeutics 2008 46 4 198 203 (Pubitemid 351493991)
33. Kalicki R. M., Aregger F., Alberio L., Lmmle B., Frey F. J., Uehlinger D. E., Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis Thrombosis and Haemostasis 2007 98 6 1200 1207 (Pubitemid 350239090)
34. Dager W. E., Kiser T. H., Systemic anticoagulation considerations in chronic kidney disease Advances in Chronic Kidney Disease 2010 17 5 420 427
35. Samama M. M., Gerotziafas G. T., Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux) Thrombosis Research 2003 109 1 1 11 (Pubitemid 36385042)
36. Klaeffling C., Piechottka G., Daemgen-von Brevern G., Mosch G., Mani H., Luxembourg B., Lindhoff-Last E., Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium Therapeutic Drug Monitoring 2006 28 3 375 381 (Pubitemid 44314925)
37. Gosselin R. C., King J. H., Janatpur K. A., Dager W. H., Larkin E. C., Owings J. T., Effects of pentasaccharide (Fondaparinux) and direct thrombin inhibitors on coagulation testing Archives of Pathology and Laboratory Medicine 2004 128 10 1142 1145 (Pubitemid 39313368)
38. Linkins L. A., Julian J. A., Rischke J., Hirsh J., Weitz J. I., In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation Thrombosis Research 2002 107 5 241 244 (Pubitemid 35435383)
39. Smogorzewska A., Brandt J. T., Chandler W. L., Cunningham M. T., Hayes T. E., Olson J. D., Kottke-Marchant K., Van Cott E. M., Effect of fondaparinux on coagulation assays: results of College of American pathologists proficiency testing Archives of Pathology and Laboratory Medicine 2006 130 11 1605 1611 (Pubitemid 44683787)
40. Depasse F., Gerotziafaz G. T., Busson J., van Dreden P., Samama M. M., Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity Journal of Thrombosis and Haemostasis 2004 2 2 346 348 (Pubitemid 40186052)
41. Cook D., Meade M., Guyatt G., Walter S., Heels-Ansdell D., Warkentin T. E., Zytaruk N., Crowther M., Geerts W., Cooper D. J., Vallance S., Qushmaq I., Rocha M., Berwanger O., Vlahakis N. E., Dalteparin versus unfractionated heparin in critically ill patients The New England Journal of Medicine 2011 364 14 1305 1314
42. Perazella M. A., Drug use and nephrotoxicity in the intensive care unit. Kidney International. In press
43. Cumbo-Nacheli G., Samavati L., Guzman J. A., Bioavailability of fondaparinux to critically ill patients Journal of Critical Care 26 4 342 346
44. Ortel T. L., Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation Hematology 2009 225 232
45. Warkentin T. E., New approaches to the diagnosis of heparin-induced thrombocytopenia Chest 2005 127 2 35S 45S (Pubitemid 40224080)
46. Prechel M., Walenga J. M., The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update Seminars in Thrombosis and Hemostasis 2008 34 1 86 96 (Pubitemid 351640884)
47. Warkentin T. E., Greinacher A., Koster A., Lincoff A. M., Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition) Chest 2008 133 6 340S 380S (Pubitemid 351892970)
48. Efird L. E., Kockler D. R., Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia The Annals of Pharmacotherapy 2006 40 7-8 1383 1387 (Pubitemid 44204970)
49. Warkentin T. E., Cook R. J., Marder V. J., Sheppard J. A. I., Moore J. C., Eriksson B. I., Greinacher A., Kelton J. G., Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin Blood 2005 106 12 3791 3796 (Pubitemid 41739014)
50. Kuo K. H. M., Kovacs M. J., Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux Thrombosis and Haemostasis 2005 93 5 999 1000 (Pubitemid 40691563)
51. Wester J. P. J., Leyte A., Oudemans-van Straaten H. M., Bosman R. J., Van der Spoel J. I., Haak E. A. F., Porcelijn L., Zandstra D. F., Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill The Netherlands Journal of Medicine 2007 65 3 101 108 (Pubitemid 46487887)
52. Blackmer A. B., Oertel M. D., Valgus J. M., Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues The Annals of Pharmacotherapy 2009 43 10 1636 1646
53. Lobo B., Finch C., Howard A., Minhas S., Fondaparinux for the treatment of patients with acute heparininduced thrombocytopenia Thrombosis and Haemostasis 2008 99 1 208 214
54. Warkentin T. E., Maurer B. T., Aster R. H., Heparin-induced thrombocytopenia associated with fondaparinux The New England Journal of Medicine 2007 356 25 2653 2654
55. Rota E., Bazzan M., Fantino G., Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT) Thrombosis and Haemostasis 2008 99 4 779 781 (Pubitemid 351694236)
56. Alsaleh K. A., Al-Nasser S. M. A., Bates S. M., Patel A., Warkentin T. E., Arnold D. M., Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis American Journal of Hematology 2008 83 11 876 878
57. Lee C. J., Ansell J. E., Direct thrombin inhibitors British Journal of Clinical Pharmacology 2011 72 4 581 592
58. Trujillo-Santos J., Nieto J. A., Ruz-Gamietea A., Lpez-Jiménez L., Garca-Bragado F., Quintavalla R., Monreal M., RIETE Investigators, Bleeding complications associated with anticoagulant therapy in patients with cancer Thrombosis Research 2010 125 S58 S61
59. Vadhan-Raj S., Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents Seminars in Hematology 2009 46 2 S26 S32
60. Ruz-Giménez N., Surez C., Gonzlez R., Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry Thrombosis and Haemostasis 2008 100 1 26 31
61. Nieto J. A., Solano R., Ruiz-Rib M. D., Ruiz-Gimenez N., Prandoni P., Kearon C., Monreal M., Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry Journal of Thrombosis and Haemostasis 2010 8 6 1216 1222
62. Crowther M. A., Warkentin T. E., Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents Blood 2008 111 10 4871 4879
63. Franchini M., Zaffanello M., Veneri D., Recombinant factor VIIa. An update on its clinical use Thrombosis and Haemostasis 2005 93 6 1027 1035 (Pubitemid 40823504)
64. Bijsterveld N. R., Moons A. H., Boekholdt S. M., Van Aken B. E., Fennema H., Peters R. J. G., Meijers J. C. M., Bller H. R., Levi M., Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers Circulation 2002 106 20 2550 2554 (Pubitemid 35340690)
65. Lisman T., Bijsterveld N. R., Adelmeijer J., Meijers J. C., Levi M., Nieuwenhuis H. K., De Groot P. G., Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux Journal of Thrombosis and Haemostasis 2003 1 11 2368 2373
66. Gerotziafas G. T., Depasse F., Chakroun T., Samama M. M., Elalamy I., Recombinant factor VIIa partially reverses the inhibitor effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood Thrombosis and Haemostasis 2004 91 3 531 537 (Pubitemid 38396875)
67. Bordes J., Asencio Y., Kenane N., Fesselet J., Meaudre E., Goutorbe P., Recombinant activated factor VII for acute subdural haematoma in an elderly patient taking fondaparinux British Journal of Anaesthesia 2008 101 4 575 576
68. Huvers F., Slappendel R., Benraad B., van Hellemondt G., van Kraaij M., Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid The Netherlands Journal of Medicine 2005 63 5 184 186 (Pubitemid 40796689)
69. Levi M., Levy J. H., Andersen H. F., Truloff D., Safety of recombinant activated factor VII in randomized clinical trials The New England Journal of Medicine 2010 363 19 1791 1800
70. Joshi A. V., Mathew P., Gore T., Cost-effectiveness of different treatment regimens consisting of NovoSeven Versus FEIBA VH for the home treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors in the United States: a cost-of-bleed model Journal of Thrombosis and Haemostasis 2005 3 supplement 1. abstract no. P2035
71. Buller H. R., Cohen A. T., Davidson B., Decousus H., Gallus A. S., Gent M., Pillion G., Piovella F., Prins M. H., Raskob G. E., Idraparinux versus standard therapy for venous thromboembolic disease The New England Journal of Medicine 2007 357 11 1094 1104 (Pubitemid 47443214)
72. van Doormaal F. F., Cohen A. T., Davidson B. L., Decousus H., Gallus A. S., Gent M., Piovella F., Prins M. H., Raskob G. E., Bller H. R., Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial Thrombosis and Haemostasis 2010 104 1 86 91
73. Dao A., Tuan B., Carlson N., Reversal of a potent investigational anticoagulant: idraparinux with recombinant factor VIIa American Journal of Medicine 2005 118 10 1172 1173 (Pubitemid 41430209)
74. Bller H. R., Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis Journal of Thrombosis and Haemostasis 2011 9 1 92 99